The ARHGAP4 Knockout A-549 Polyclonal Cells product comprises a heterogeneous, CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This model carries a targeted disruption of the ARHGAP4 gene, resulting in loss-of-function of the encoded Rho GTPase-activating protein. The polyclonal format retains the genetic diversity inherent to a CRISPR-edited pool, allowing researchers to observe phenotypic consequences at the population level without clonal selection biases.
The A-549 host cell line was originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and exhibits a hypotriploid karyotype. These epithelial cells serve as a widely accepted model of human alveolar type II epithelium, enabling investigation of respiratory biology and oncogenic transformation. A-549 cells are routinely employed in studies of lung cancer biology, drug response, and metastasis due to their robust in vitro growth and well-characterized signaling networks.
ARHGAP4 functions as a GTPase-activating protein (GAP) that selectively accelerates GTP hydrolysis on Rho family GTPases, including RhoA, Rac1, and Cdc42, thereby converting them to their inactive GDP-bound states. By diminishing the active pools of these molecular switches, ARHGAP4 attenuates downstream actin polymerization and actomyosin contractility. Specifically, reduced RhoA-GTP levels lead to decreased activation of ROCK1 and LIMK, impairing cofilin phosphorylation and stress fiber formation. Similarly, lower Rac1-GTP and Cdc42-GTP levels suppress the WAVE complex and Arp2/3-mediated actin branching, ultimately limiting lamellipodial and filopodial protrusions. Thus, ARHGAP4 serves as a critical negative regulator of cytoskeletal remodeling, focal adhesion turnover, and cell migration.
In the A-549 lung adenocarcinoma background, ARHGAP4 knockout is expected to disrupt normal regulatory constraints on Rho GTPase signaling, leading to aberrant activation of actin polymerization pathways. The consequent alterations in stress fiber organization, focal adhesion dynamics, and actomyosin contractility likely impact cellular morphology, adhesion, and directional migration. Given the pivotal roles of Rho GTPases in tumor cell invasion and metastatic dissemination, this knockout model provides a physiologically relevant platform to dissect ARHGAP4??s contribution to lung adenocarcinoma progression. The A-549 lineage also permits integration with established assays for epithelial-mesenchymal transition and anoikis resistance, offering broader insights into cancer cell plasticity.
This polyclonal knockout cell population is ideally suited for a range of functional studies, including wound healing and Transwell migration/invasion assays to quantify cell motility, phalloidin staining to visualize F-actin architecture, and Rho GTPase activity assays (e.g., G-LISA or effector pull-down) to map signaling changes. Complementary techniques such as Western blotting can probe downstream effectors like phospho-cofilin, ROCK1, or WAVE complex components. Researchers investigating mechanisms of cancer metastasis, actin cytoskeleton regulation, or Rho GTPase signaling will find this model a powerful tool for hypothesis-driven studies. For additional technical information, protocol recommendations, or ordering details, please contact Ascent Research.
